Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Plunges On Mixed Phase 3 Results In Geographic Atrophy
10:29am, Friday, 17'th Sep 2021
Apellis Plunges On Mixed Phase 3 Results In Geographic Atrophy
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
03:00pm, Thursday, 16'th Sep 2021
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
01:29pm, Monday, 13'th Sep 2021
Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.
APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today
01:32pm, Friday, 10'th Sep 2021
Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results. The post APLS Stock: The Trial Results That Have Apellis Pharmaceuticals
Why Apellis Pharmaceutical Shares Are Plunging Today
12:49pm, Friday, 10'th Sep 2021
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary endpoint of GA lesion growth. D
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
10:52am, Friday, 10'th Sep 2021
Conflicting clinical trial results for the company's lead candidate are to blame.
Apellis Stock Plunges After Its Eye Treatment Gets Mixed Results
09:20am, Friday, 10'th Sep 2021
Apellis Pharmaceuticals releases mixed results for its eye disease treatment and the stock falls sharply.
Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies
08:00am, Friday, 10'th Sep 2021
Shares of Apellis Pharmaceuticals Inc. APLS, +0.05% plunged 31.6% toward a 10-month low to pace all premarket losers Friday, after one of the Phase 3 studies of the biopharmaceutical company's eye dis
Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line
06:35am, Friday, 10'th Sep 2021
Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed showing, CEO Cedric Francois thinks the c
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today reported top-line results from the
Apellis Pharmaceuticals, Inc. (APLS) Down 6.8% Since Last Earnings Report: Can It Rebound?
01:16pm, Wednesday, 08'th Sep 2021
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 07'th Sep 2021
WALTHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compa
WALTHAM, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compa
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
11:00am, Wednesday, 11'th Aug 2021
Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.
Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates
05:03pm, Tuesday, 10'th Aug 2021
Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.
